Savara to Present at the Barclays 26th Annual Global Healthcare Conference
07 3월 2024 - 6:05AM
Business Wire
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical
company focused on rare respiratory diseases, today announced that
its management team will participate in a fireside chat at the
Barclays 26th Annual Global Healthcare Conference on March 14, 2024
at 5:00am PT/8:00am ET. A live webcast of the fireside chat will be
available on Savara’s website at
www.savarapharma.com/investors/events-presentations/ and will be
archived for 90 days.
About Savara Savara is a clinical stage biopharmaceutical
company focused on rare respiratory diseases. Our lead program,
molgramostim nebulizer solution, is an inhaled
granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase
3 development for autoimmune pulmonary alveolar proteinosis (aPAP).
Molgramostim is delivered via an investigational eFlow® Nebulizer
System (PARI Pharma GmbH). Our management team has significant
experience in rare respiratory diseases and pulmonary medicine,
identifying unmet needs, and effectively advancing product
candidates to approval and commercialization. More information can
be found at www.savarapharma.com. (X, formerly known as Twitter:
@SavaraPharma, LinkedIn:
www.linkedin.com/company/savara-pharmaceuticals/).
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240306913347/en/
Savara Inc. IR & PR Anne Erickson
anne.erickson@savarapharma.com (512) 851-1366
Savara (NASDAQ:SVRA)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Savara (NASDAQ:SVRA)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024